key: cord-0929027-zg2u7fwx
authors: Han, Yuling; Yang, Liuliu; Duan, Xiaohua; Duan, Fuyu; Nilsson-Payant, Benjamin E.; Yaron, Tomer M.; Wang, Pengfei; Tang, Xuming; Zhang, Tuo; Zhao, Zeping; Bram, Yaron; Redmond, David; Houghton, Sean; Nguyen, Duc; Xu, Dong; Wang, Xing; Uhl, Skyler; Huang, Yaoxing; Johnson, Jared L.; Xiang, Jenny; Wang, Hui; Pan, Fong Cheng; Cantley, Lewis C.; tenOever, Benjamin R.; Ho, David D.; Evans, Todd; Schwartz, Robert E.; Chen, Huanhuan Joyce; Chen, Shuibing
title: Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids
date: 2020-05-05
journal: bioRxiv
DOI: 10.1101/2020.05.05.079095
sha: aa2dfb1bad9aa849fded4324ecff9f3ba99184be
doc_id: 929027
cord_uid: zg2u7fwx

The SARS-CoV-2 virus has caused already over 3.5 million COVID-19 cases and 250,000 deaths globally. There is an urgent need to create novel models to study SARS-CoV-2 using human disease-relevant cells to understand key features of virus biology and facilitate drug screening. As primary SARS-CoV-2 infection is respiratory-based, we developed a lung organoid model using human pluripotent stem cells (hPSCs) that could be adapted for drug screens. The lung organoids, particularly aveolar type II cells, express ACE2 and are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection revealed a robust induction of chemokines and cytokines with little type I/III interferon signaling, similar to that observed amongst human COVID-19 pulmonary infections. We performed a high throughput screen using hPSC-derived lung organoids and identified FDA-approved drug candidates, including imatinib and mycophenolic acid, as inhibitors of SARS-CoV-2 entry. Pre- or post-treatment with these drugs at physiologically relevant levels decreased SARS-CoV-2 infection of hPSC-derived lung organoids. Together, these data demonstrate that hPSC-derived lung cells infected by SARS-CoV-2 can model human COVID-19 disease and provide a valuable resource to screen for FDA-approved drugs that might be repurposed and should be considered for COVID-19 clinical trials.

The ongoing COVID-19 pandemic is an unprecedented global event that requires the immediate deployment of effective clinical therapeutics while vaccine candidates are identified and tested.

Arguably the most rapid means of addressing this issue is through the repurposing of existing drugs that are FDA-approved which may indirectly interfere with aspects of SARS-CoV-2 biology.

While this strategy is being pursued, most high throughput screens focus on the use of transformed cell lines which fail to capture the physiologically relevant dynamics of a SARS-CoV-2 infection.

In an effort to improve on these cell lines, we developed and describe here lung organoids as an improved in vitro platform for screening purposes.

In the last several years, a series of protocols have been reported to direct hPSC differentiation to various lung lineages [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . We differentiated hPSCs to lung organoids using a previously reported stepwise strategy 4, 15 , including the progressive differentiation first into definitive endoderm (DE), followed by specification to anterior foregut endoderm (AFE), AFE/lung progenitor cells (LPs), and finally lung organoids (Extended Data Fig. 1) . Single cell transcriptomic profiles were generated and analyzed in the differentiated lung organoids at day 50 and identified alveolar type II (AT2) cells (SP-B + , SP-D + , ABCA3 + ), alveolar type I (AT1) cells (PDPN + APQ5 + ), stromal cells, and proliferating cells (Fig. 1a, 1b and Extended Data Fig. 2b) . We also detected a low number of pulmonary neuroendocrine cells (ASCL1 + , CALCA + ) and airway epithelial cells ( Fig. 1a and Extended Data Fig. 2a, 2b) . ACE2, the putative receptor for SARS-CoV-2 16 , is mainly detected in cluster 1, which represents AT2 cells (Fig. 1c, 1d) . TMPRSS2, a key transmembrane protease for SARS-CoV-2 infection 16 , is also enriched in AT2 cells and AT1 cells (Fig. 1c, 1d) . Consistent with scRNA-seq data of adult lung 17 , ACE2 and TMPRSS2 expression are detected in only a subset of the AT2 cells, likely due to the depth limitation of 10X scRNA-seq. Immunostaining results further validated that ACE2 is expressed in SP-B + /SP-C + AT2 cells (Fig. 1e) .

To determine the relative permissiveness of hPSC-derived lung organoids to SARS-CoV-2 viral entry, we first used a vesicular stomatitis virus (VSV) based SARS-CoV-2 pseudo-entry virus, for which the backbone was provided by a VSV-G pseudo-typed ΔG-luciferase virus with the SARS-CoV-2 Spike protein incorporated at the surface of the viral particle (See Methods for details) 18, 19 .

Robust luciferase activity was readily detected in the infected hPSC-derived lung organoids (Fig.   1f ).

To generate an in vivo model using human lung organoids, we implanted subcutaneously day 25 lung progenitor cells in immuno-deficient NSG mice (Fig. 1g) . Within 4 months the xenografts developed organized alveolar-like structures (Fig. 1h) . Immunostaining confirms the existence of SP-B + AT2 cells, which co-express ACE2 (Fig. 1i) . Infection of SARS-CoV-2 pseudo-entry virus was tested in this mouse model carrying hPSC-derived lung xenografts. Expression of luciferase from the SARS-CoV-2 pseudo-entry virus was detected by immunofluorescence staining 24 hours after intra-xenograft inoculation (1X10 4 FFU). LUC is mainly detected in SP-B + AT2 cells (Fig.   1j ).

The potential of the hPSC-derived lung organoid platform to model COVID-19 was then tested by infection with SARS-CoV-2 virus in the cultures. 24 hours post inoculation (hpi) with the SARS-CoV-2 virus (USA-WA1/2020, MOI=0.01), qRT-PCR using primers targeting N sgRNA transcripts confirmed that a significant amount of replicating viral RNA was detected in the infected lung organoids (Fig. 2a) . Immunostaining confirmed the detection of SARS-S protein in the infected lung organoids (Fig. 2b) . At 24 hpi, RNA-seq was performed on mock and SARS-CoV-2 infected cells. Alignment with the viral genome confirmed robust viral replication in hPSCderived lung organoids (Fig. 2c) . Moreover, plotting these datasets by principle component analysis (PCA) suggested that the infected lung organoids clustered distinctly compared to mockinfected lung organoids (Fig. 2d) . Volcano plots of SARS-CoV-2 infected hPSC-derived lung organoids compared to mock treatment revealed robust induction of chemokines and cytokines with no detectable levels of type I and III IFNs (Fig. 2e) . Gene set enrichment analysis (GSEA) comparing mock-infected versus SARS-CoV-2 infected lung organoids revealed over-represented pathway networks including TNF signaling, IL-17 signaling, chemokine signaling pathway, and cytokine-cytokine receptor interaction (Fig. 2f) . These profiles were further compared with primary tissues from healthy and COVID-19 patients. Compared with healthy lung, lung tissues of COVID-19 patients revealed robust induction of chemokines, including CXCl2, CCL2, CXCL3 as well as IL1A, BCRC3, AADAC, and ATPB4 (Fig. 2g) , which is markedly similar to SARS-CoV-2 infected lung organoids. Finally, IL-17 signaling was also found to be significantly changed in lung tissues of COVID-19 patients, which is consistent with SARS-CoV-2 infected lung organoids ( Fig. 2h) .

To identify drug candidates capable of blocking SARS-CoV-2 pseudo-virus infection, hPSCderived lung organoids were deposited onto 384-well plates. After six hour of incubation, organoids were treated at 10 μM with a library of FDA-approved drugs (the Prestwick collection).

Two hour post-treatment, the organoids were innoculated with SARS-CoV-2 pseudo-entry virus at MOI=0.01. At 24 hpi, the organoids were analyzed for luciferase activity. The wells in which Z score<-2 were chosen as primary hit drugs (Fig. 3a) . The hits were evaluated for efficacy and cytotoxicity at different concentrations. Four drugs were confirmed to block luciferase activity in a dose-dependent manner, independent of cytotoxicity, including imatinib (EC50=4.86 μM, Fig. 3b, 3e) , mycophenolic acid (MPA, EC50=0.15 μM, Fig. 3c, 3f) , quinacrine dihydrochloride (QNHC, EC50=2.83 μM, IC50=22 μM, Fig. 3d, 3g) , chloroquine (EC50=3.85 μM), and prochlorperazine (EC50=23.7 μM, IC50=30 μM) (Extended Data Fig. 3) . Interestingly, three hit compounds, MPA, QNHC, and chloroquine, were also identified from our independent screen using hPSC-derived colonic organoids 20 . Immunostaining confirmed a significant diminishment of LUC + cells detected among SP-C + AT2 cells in lung organoids treated with 10 µM imatinib, 3 µM MPA or 4.5 µM QNHC at 24 hpi (Fig. 3h) .

To evaluate the drug activities in vivo, we used humanized mice carrying hPSC-derived lung xenografts after 4 months maturation in vivo (Fig. 3i) . The humanized mice were treated with 400 mg/kg imatinib mesylate, 50 mg/kg MPA, or 25 mg/kg QNHC. 3 hours post-treatment, SARS-CoV-2 pseudo-entry virus (1X10 4 FFU) was delivered by intra-xenograft inoculation. At 24 hpi, luciferase staining was detected in mice treated with vehicle. The number of LUC + cells was significantly decreased in mice treated with imatinib mesylate, MPA or QNHC (Fig. 3j, 3k) .

Finally, hPSC-derived lung organoids pre-treated with 10 µM imatinib, 3 µM MPA or 4.5 µM QNHC were infected with SARS-CoV-2 virus at MOI=0.5. At 24 hpi, qRT-PCR confirmed significantly decreased replicating viral RNA in lung organoids treated with imatinib, MPA or QNHC (Fig. 4a) . Immunostaining confirmed a significant loss of SARS-CoV-2 + cells in imatinib, MPA or QNHC-treated hPSC derived-lung organoids (Fig. 4b) .

To determine the therapeutic potential of imatinib, MPA and QNHC, hPSC-derived lung organoids were infected with SARS-CoV-2 virus (MOI=0.5). Three hours later, lung organoids were treated with 10 µM imatinib, 3 µM MPA or 4.5 µM QNHC. At 24 hpi, both viral RNA (Fig. 4c) and SARS-CoV-2 + cells ( Fig.   4d ) were significantly decreased in the lung organoids treated with each drug, highlighting the therapeutic potential. Transcriptional profiling was applied to compare DMSO and imatinibtreated lung organoids, and PCA plots showed these clustered separately (Fig. 4e) . Volcano plots and GSEA analysis highlight the change of pathways caused by imatinib, related to fatty acid biosynthesis, steroid biosynthesis, fatty acid metabolism, and PPAR signaling pathway (Fig. 4f,   4g ). Viruses have been known to target lipid signaling, synthesis, and metabolism to remodel their host cells into an optimal environment for their replication. Fatty acid is involved in multiple steps of viral circle, including membrane fusion during the entry process, virion envelopment during particle maturation, as well as virus replication 21 . The fact that fatty acid biosynthesis and metabolism pathways are changed in the imatinib-treated lung organoids suggests that imatinib might also affect virus replication and particle maturation. Finally, qRT-PCR and western blotting experiments confirmed the ability of imatinib to block anti-SARS-CoV-2 activity in Vero cells (Extended Data Fig. 4) .

The lung is the most vulnerable target organ for the SARS-CoV-2 virus, and respiratory failure is the primary disease outcome for COVID-19. Yet the primary model currently used for SARS-CoV-2 studies are African green monkey kidney derived Vero cells, which have clear limitations for modeling complex human pulmonary or other organ systems. Therefore, the development of physiologically relevant human cell models to study SARS-CoV-2 infection is critically important.

Here, we present an hPSC-derived lung organoid platform, including SP-B + AT2 cells that express ACE2 and TMPRSS2, two key factors involved in SARS-CoV-2 infection, which is consistent with the previous reports 22 . RNA-seq of infected organoids revealed upregulation of cytokine/chemokine signaling, which phenocopies the cytokine and chemokine changes observed in primary human COVID-19 pulmonary infection 23 . Finally, we used the hPSC-derived lung organoids in a high throughput screen for FDA-approved drugs. We identified several drugs that decreased the luciferase activity of SARS-CoV-2 pseudo-entry virus including imatinib, MPA and QNHC, both in vitro and in vivo. The anti-viral activity of these drugs was further validated against patient-derived SARS-CoV-2 virus.

Imatinib is an inhibitor of a number of tyrosine kinase enzymes, including Abl, c-kit, PDGF-R and others. Previous studies have also suggested imatinib as a potent inhibitor of SARS and MERS coronavirus fusion proteins 24 . Using HIV SARS-S and MERS-S pseudotyped virions, imatinib was shown to substantially block coronavirus S protein-induced fusion and prevent endosomal entry 25 . Imatinib has been widely used to treat chronic myelogenous leukemia and other cancers, and should be considered for repurposing as a drug candidate for COVID-19 patients. Very recently, three clinical trials (ClinicalTrials.gov Identifier: NCT04346147, NCT04357613, NCT04356495) were registered to apply imatinib to treat COVID-19 patients. Our study provides experimental data to support these trials. Data was presented as mean ± STDEV. P values were calculated by unpaired two-tailed Student's t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Data was presented as mean ± STDEV. P values were calculated by unpaired two-tailed Student's t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Data was presented as mean ± STDEV. P values were calculated by unpaired two-tailed Student's t test. *P < 0.05, **P < 0.01, and ***P < 0.001. I.U./mL penicillin and 100 μg/mL streptomycin. All cell lines were incubated at 37°C with 5%

CO2.

Recombinant Indiana VSV (rVSV) expressing SARS-CoV-2 spikes was generated as previously described 18, 19, 26 . HEK293T cells were grown to 80% confluency before transfection with pCMV3-SARS-CoV2-spike (kindly provided by Dr. Peihui Wang, Shandong University, China)

using FuGENE 6 (Promega). Cells were cultured overnight at 37°C with 5% CO2. The next day, the media was removed and VSV-G pseudotyped ΔG-luciferase (G*ΔG-luciferase, Kerafast) was used to infect the cells in DMEM at an MOI of 3 for 1 hr before washing the cells with 1X DPBS three times. DMEM supplemented with 2% FBS and 100 I.U. /mL penicillin and 100 μg/mL streptomycin was added to the infected cells and they were cultured overnight as described above.

The next day, the supernatant was harvested and clarified by centrifugation at 300xg for 10 min before aliquoting and storing at −80°C.

SARS-CoV-2, isolate USA-WA1/2020 (NR-52281) was deposited by the Center for Disease 

For lung organoids, organoids were seeded in 24-well plates, pseudo-typed virus was added for MOI=0.01 and centrifuged the plate at 1200g, 1 hour. At 24 hpi, organoids were fixed for immunohistochemistry or harvested for luciferase assay following the Luciferase Assay System protocol (E1501, Promega)

hESC-derived lung organoids were infected with SARS-CoV-2 at the indicated MOI and Harbor, Maine). When xenograft size becomes 1-2 CM 3 , they were sacrificed immediately, necropsy performed, and cells were harvested for further histological or molecular study.

Histology on tissues from mice was performed on paraffin-embedded or frozen sections from xenografts and corresponding normal tissues as previously described 27 . Tissues were fixed overnight in 10% buffered formalin and transferred to 70% ethanol, followed by paraffin embedding, or tissues were fixed in 10% buffered formalin and transferred to 30% sucrose, For immunofluorescence, cells or tissue sections were immunostained with primary antibodies at 4°C overnight and secondary antibodies at RT for 1h. The information for primary antibodies and secondary antibodies are provided in Table S3 . Nuclei were counterstained by DAPI.

Protein antibodies. Antibody-mediated fluorescence was detected on a LI-COR Odyssey CLx imaging system and analyzed using Image Studio software (LI-COR).

Total RNA samples were prepared from cells/organoids using TRIzol and Direct-zol RNA Table S4 .

We filtered cells with less than 200 or more than 6000 genes detected as well as cells with mitochondria gene content greater than 30%, and used the remaining 14263 cells for downstream analysis. We normalized the gene expression UMI counts using a deconvolution strategy implemented by the R scran package (v.1.14.1). In particular, we pre-clustered cells using the quickCluster function; we computed size factor per cell within each cluster and rescaled the size factors by normalization between clusters using the computeSumFactors function; and we normalized the UMI counts per cell by the size factors and took a logarithm transform using the normalize function. We identified highly variable genes using the FindVariableFeatures function in the R Seurat (v3.1.0) 28 , and selected the top 3000 variable genes after excluding mitochondria genes, ribosomal genes and dissociation-related genes. The list of dissociation-related genes was originally built on mouse data 29 ; we converted them to human ortholog genes using Ensembl BioMart. We scaled the normalized counts and performed PCA on the highly variable genes using the ScaleData and RunPCA functions in the R Seurat package 28 . We selected the top 20 PCs for downstream visualization and clustering analysis. We ran UMAP dimensional reduction using the RunUMAP function in the R Seurat package with the number of neighboring points setting to 35 and training epochs setting to 500. We clustered cells into fifteen clusters by constructing a shared nearest neighbor graph and then grouping cells of similar transcriptome profiles using the FindNeighbors function and FindClusters function (resolution set to 0.2) in the R Seurat package.

We identified marker genes for each cluster by performing differential expression analysis between cells inside and outside that cluster using the FindMarkers function in the R Seurat package. After reviewing the clusters, we merged them into nine clusters representing nine cell types (AT1 cells, AT2 cells, bronchiolar epithelial cells, stromal cells_1, stromal cell_2, proliferating cells, stromal cells_3, pulmonary neuroendocrine cells (PNEC) and airway epithelial cells) for further analysis. We re-identified marker genes for the merged nine clusters and selected top positive marker genes per cluster for heatmap plot using the DoHeatmap function in the R Seurat package. The rest plots were generated using the R ggplot2 package.

Organoid infections were performed at an MOI of 0.1 and harvested at 24 hpi in DMEM supplemented with 0.3% BSA, 4.5 g/L D-glucose, 4 mM L-glutamine and 1 μg/ml TPCKtrypsin. After further filtering and quality control, R package edgeR 31 was used to calculate RPKM and Log2 counts per million (CPM) matrices as well as perform differential expression analysis.

Principal component analysis was performed using Log2 CPM values and gene set analysis was run with WebGestalt 32 . Heatmaps and bar plots were generated using Graphpad Prism software, version 7.0d.

hPSC-derived lung organoids were dissociated using TrypLE for 10 min in a 37℃ waterbath and replated into 10% Matrigel-coated 384-well plates at 10,000 cells/40 µl medium/well. Six hour after plates, compounds from an in-house FDA-approved drug library (Prestwick) were added at 10 µM. DMSO treatment was used as a negative control. Two hours late, cells will be infected with SARS-CoV-2 pseudo virus (MOI=0.01). After 24 hpi, hPSC-COs were harvested for luciferase assay following the Luciferase Assay System protocol (Promega).

N=3 independent biological replicates were used for all experiments unless otherwise indicated.

n.s. indicates a non-significant difference. P-values were calculated by unpaired two-tailed Student's t-test unless otherwise indicated. *p<0.05, **p<0.01 and ***p<0.001. 

Extended Data Figure 4. Imatinib shows anti-SARS-CoV-2 activity on Vero cells. a, qRT-PCR analysis of DMSO or 10 µM imatinib treated Vero cells at 24 hpi (SARS-CoV-2

Data was presented as mean ± STDEV. P values were calculated by unpaired two-tailed Student's t test. *P < 0.05, **P < 0.01, and ***P < 0.001. b, c,Western blotting (b) and quantification (c) of DMSO or 10 µM imatinib treated Vero cells at 24 hpi

Author Contribution

Y performed organoid differentiation, in vivo transplantation, pseudo-virus infection and drug screening

performed SARS2-CoV-2 pseudo-entry virus related experiments

performed the scRNA-sequencing and bioinformatics analyses

The authors have no conflict of interest. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals. L.C.C. is an inventor on patents (pending) for Combination Therapy for PI3K-associated Disease or Disorder, and The Identification of Therapeutic Interventions to Improve Response to PI3K Inhibitors for Cancer Treatment. L.C.C. is a co-founder and shareholder in Faeth Therapeutics

A revised airway epithelial hierarchy includes CFTR-expressing ionocytes

A three-dimensional model of human lung development and disease from pluripotent stem cells

The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells

Efficient generation of lung and airway epithelial cells from human pluripotent stem cells

Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs

Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells

Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells

Efficient Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling

Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors

Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells

Generation of lung organoids from human pluripotent stem cells in vitro

In vitro generation of human pluripotent stem cell derived lung organoids

In Vitro Induction and In Vivo Engraftment of Lung Bud Tip Progenitor Cells Derived from Human Pluripotent Stem Cells

Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Multifaceted roles for lipids in viral infection

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability

Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis

Comprehensive Integration of Single-Cell Data

Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations

STAR: ultrafast universal RNA-seq aligner

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs

RNA-seq data is available from the GEO repository database with accession number GSE148697.